Molbio Diagnostics' ₹940 crore IPO allotment status is expected to be finalized today, Thursday, August 13, 2026, after the issue received 70.26 times oversubscription as of 17:30 IST on August 12. The Goa-based company's IPO received bids for 57.32 crore shares against 81.58 lakh shares on offer, with the subscription pattern showing qualified institutional buyers leading at 186.39 times, non-institutional investors at 49.80 times, and retail individual investors at 12.96 times. Shares of Molbio Diagnostics will debut on both NSE and BSE on Monday, August 17, at 10 am. Investors can check their allotment status online through NSE, BSE, or KFin Technologies websites using their application number and PAN details. The IPO, which opened on August 10 and closed on August 12, comprised a fresh issue of ₹200 crore and an offer for sale (OFS) of 91.66 lakh shares worth ₹739.70 crore, with the company fixing the price band at ₹768-₹807 per share.
The company delivered robust financial performance between FY24 and FY26, with revenue growing at a compound annual growth rate (CAGR) of 31.5%. In FY26 specifically, net profit rose 18% year-on-year to ₹164.14 crore, while revenue increased 42% to ₹1,445.69 crore from ₹1,027 crore in FY25. EBITDA stood at ₹328.24 crore in FY26, up from ₹256.64 crore in FY25. As reported by The Economic Times, this strong financial trajectory supports the company's position as a leading player in point-of-care molecular diagnostics. The company reported consolidated net profit of ₹166.59 crore and sales of ₹1,445.69 crore for the twelve months ended March 31, 2026. Revenue from operations in FY24, FY25, and FY26 were ₹836.56 crore, ₹1,020.42 crore, and ₹1,445.69 crore, respectively, with net profit attributable to the owners of the parent increasing from ₹83.54 crore in FY24 to ₹138.58 crore in FY25 and ₹164.14 crore in FY26.
The grey market is indicating strong demand for the Molbio Diagnostics IPO, with the latest grey market premium (GMP) at ₹156, translating to a potential listing gain of ₹156 per share over the upper price band of ₹807. According to LiveMint, this represents an increase from earlier reported figures, with the estimated listing price around ₹963 per share, which is 19.33% higher than the IPO price of ₹807. The grey market premium has climbed from earlier levels, with grey market trends over the past 10 sessions showing the GMP fluctuating between ₹0.00 and ₹220, pointing to expectations of a strong debut on the stock exchanges. Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are serving as the book-running lead managers for the issue, while KFin Technologies Ltd. is acting as the registrar. Investors can verify their allotment through either the registrar's website (ipostatus.kfintech.com) or NSE's IPO allotment page using their application number and PAN details.
Molbio Diagnostics is a point-of-care diagnostics company founded in October 2000, primarily known for its proprietary Truenat platform, a portable, battery-powered PCR-based molecular diagnostic system that can provide accurate test results within an hour. As of March 31, 2026, over 12,500 Truenat devices were installed across more than 90 countries, with revenue primarily generated from devices and recurring sales of proprietary Truenat test kits. In FY26, devices, test kits and other products contributed 14.53%, 73.98% and 11.49% of total sales, respectively, while exports accounted for 9.6% of revenue. The company has expanded into digital imaging, digital pathology and breast health screening through acquisitions, investments and partnerships. The company offers molecular testing for 30 diseases, including tuberculosis, COVID, Hepatitis B and C, HIV, and HPV, with 43 assays. Molbio is a molecular diagnostic company that develops, manufactures, and commercialises point-of-care (POC) molecular diagnostic platforms, focusing on providing rapid, accurate, and cost-effective diagnostic solutions for infectious and non-communicable diseases.
Molbio Diagnostics successfully raised ₹281.5 crore from anchor investors ahead of its public issue opening. According to the company's exchange filing dated August 7, the company allotted 34.87 lakh equity shares to 33 anchor investors at ₹807 per share, the upper end of the IPO price band. Among the anchor investors, Goldman Sachs invested ₹30 crore, while the International Finance Corporation (IFC) and BlackRock Global Funds invested ₹20 crore each. Domestic mutual funds accounted for a significant portion with 23.54 lakh shares allotted to nine domestic mutual funds through 19 schemes, including HDFC Mutual Fund, Kotak Mahindra Asset Management Company, ICICI Prudential Asset Management Company, Nippon India Mutual Fund, Mirae Asset, WhiteOak Capital, Motilal Oswal Asset Management Company, Tata Mutual Fund and Edelweiss Mutual Fund. The company also allotted 2.65 lakh shares worth ₹21.44 crore to 10 life insurance companies. From the net issue, Molbio Diagnostics proposes to utilize ₹105.5 crore towards capital expenditure for establishing infrastructure for an R&D facility and Centre of Excellence through its subsidiary Bigtec, while ₹72.2 crore will be used towards the purchase of plant, machinery and other equipment for its manufacturing facilities in Goa and Visakhapatnam. The remaining proceeds will be used for general corporate purposes.
The ₹200 crore fresh issue will fund capacity expansion at the Goa and Visakhapatnam facilities, with the remaining OFS component being sold by existing shareholders including Exxora Trading LLP, Dr Chandrasekhar Bhaskaran Nair, India Business Excellence Fund III, Gopalkrishna Mangalore Kini, and J. Guru Dutt. The promoters are Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP, who hold an aggregate of 5,25,97,450 equity shares, aggregating to 46.65% of the pre-offer issued and paid-up equity share capital, with their post-IPO shareholding expected to be around 43.01%. The Truenat platform is patented in over 100 countries for diagnosis of various infectious and non-communicable diseases, making it suitable for resource-limited settings and facilitating decentralised diagnosis within an hour. The ₹105.5 crore from fresh issue proceeds will be utilized towards capital expenditure for establishing infrastructure for an R&D facility, Centre of Excellence and connected office space, while ₹72.2 crore will be used towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit. A significant portion of the funds, approximately ₹125.12 crore, will be invested in capital expenditure for developing a research and development facility, Centre of Excellence, and related office infrastructure. The company plans to expand its product portfolio, international presence and diagnostic capabilities through new assays, POC platforms, strategic acquisitions, partnerships and the planned Centre of Excellence in Bengaluru.
